Document is current
Any future updates will be listed below
-
Authors
Williams, Jack https://orcid.org/0000-0002-1331-387X
Vickerman, Peter https://orcid.org/0000-0002-8291-5890
Smout, Elizabeth
Page, Emma E.
Phyu, Khine
Aldersley, Mark
Nebbia, Gaia
Douthwaite, Sam
Hunter, Laura
Ruf, Murad
Miners, Alec https://orcid.org/0000-0003-1850-1463
-
Funding
Funding for this research was provided by:
Gilead UK and Ireland Corporate Contributions
National Institute for Health Research Health Protection Research Unit
- License Information
-
More Information
Article History
Received: 21 March 2022
Accepted: 24 September 2022
First Online: 14 November 2022
Declarations
:
: The economic analysis received ethical approval from the London School of Hygiene and Tropical Medicine (Ref: 14668). The analysis did not involve any primary data collection.
: Not applicable.
: JW and AM received a research grant from Gilead Sciences for this project. EP reports receiving a grant from Gilead Sciences for a joint working BBV testing project at Leeds Teaching Hospital Trust. MA has participated in advisory board meetings and received educational grants from Gilead Sciences, MSD and Abbvie. SD has previously received grants and travel bursaries from Gilead Sciences. MR is an employee of Gilead Sciences. LH, GN, ES, KP and PV report no competing interests.
